Basilea 从辉瑞公司赚取了 $2.5M，用于抗真菌药物 Cresemba 在亚洲和中国的销售成功。 Basilea earns $2.5M from Pfizer for antifungal drug Cresemba's sales success in Asia and China.

由辉瑞公司销售的 Basilea Pharmaceutica 的抗真菌药物 Cresemba 在亚太和中国的销售里程碑，促使 Basilea 获得了 250 万美元的付款。 Basilea Pharmaceutica's antifungal drug Cresemba, marketed by Pfizer, hit sales milestones in Asia Pacific and China, triggering a $2.5 million payment to Basilea. Cresemba在2024年的全球销售额达到5.62亿美元,比上一年增加19%,成为全世界最具品牌的侵入性真菌感染抗风疹。 Cresemba's global sales in 2024 reached $562 million, up 19% from the previous year, making it the top branded antifungal for invasive fungal infections worldwide. 这一强的销售额反映了全球对新型抗真菌药物的需求日益增长. The strong sales reflect growing global demand for new antifungal treatments.